[HTML][HTML] Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo-and radiation …
L Qi, H Lindsay, M Kogiso, Y Du, FK Braun… - Laboratory …, 2022 - Elsevier
Brain tumors are the leading cause of cancer-related death in children. Tazemetostat is an
FDA-approved enhancer of zeste homolog (EZH2) inhibitor. To determine its role in difficult-
to-treat pediatric brain tumors, we examined EZH2 levels in a panel of 22 PDOX models and
confirmed EZH2 mRNA over-expression in 9 GBM (34.6±12.7-fold) and 11 medulloblastoma
models (6.2±1.7 in group 3, 6.0±2.4 in group 4) accompanied by elevated H3K27me3
expression. Therapeutic efficacy was evaluated in 4 models (1 GBM, 2 medulloblastomas …
FDA-approved enhancer of zeste homolog (EZH2) inhibitor. To determine its role in difficult-
to-treat pediatric brain tumors, we examined EZH2 levels in a panel of 22 PDOX models and
confirmed EZH2 mRNA over-expression in 9 GBM (34.6±12.7-fold) and 11 medulloblastoma
models (6.2±1.7 in group 3, 6.0±2.4 in group 4) accompanied by elevated H3K27me3
expression. Therapeutic efficacy was evaluated in 4 models (1 GBM, 2 medulloblastomas …